js107
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 26, 2022 (NCT05502393)
Timeline
Indications
Mechanism of action
- Claudin-18INHIBITOR
CLDN18 inhibitor
Chemistry & pharmacology
- Payload
- MMAE
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07284134 | Phase 3 | Dec 20, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT05657418 | Phase 1 | Dec 30, 2022 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT05502393 | Phase 1 | Jul 26, 2022 | Shanghai Junshi Bioscience Co.,Ltd., Sun Yat-Sen University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 3 | 3 | 2 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1